Long-Term Opioid Therapy for Pain

Key Points

• Understanding of opioid-related risks remains incomplete, emphasizing the need for better data.
• FDA data reveals concerning opioid harms, necessitating improved regulatory actions.
• Call for postmarketing studies aligns with the goal of enhancing pain care safety and effectiveness.
• Clearer regulatory communication is essential for effective pain therapeutics management.

Abstract